Inhibrx Biosciences, Inc. announced on March 19 its financial results for the fourth quarter and full fiscal year of 2025. The company reported cash and cash equivalents totaling $124.2 million as of December 31, 2025, and noted it had secured an additional $75 million in gross proceeds through a loan agreement with Oxford Finance, LLC on March 18.
The announcement follows significant corporate changes in May 2024, when Inhibrx completed the sale of its INBRX-101 program to Sanofi S.A. and underwent a spin-off from its former parent company. As a result, Inhibrx now operates as a clinical-stage biopharmaceutical company with two ongoing clinical programs: ozekibart and INBRX-106.
According to the company, both therapeutic candidates utilize multivalent formats that allow for optimization based on specific targets. Inhibrx said it plans several milestones in the coming months, including submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration early in the second quarter of 2026 for ozekibart, announcing data from its colorectal cancer expansion cohort, meeting with regulators about accelerated approval for Ewing sarcoma and fourth-line colorectal cancer indications, and presenting new data at the ESMO Congress later that year.
The company cautioned investors about forward-looking statements related to safety and efficacy outcomes for ozekibart based on interim or topline results. “Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx’s business,” Inhibrx said in its statement.
PR Newswire operates in more than 170 countries and supports distribution in over 40 languages according to the official website. The service aims to deliver global reach for press release distribution through its network of newsrooms and influencers as detailed on its official website. PR Newswire features expert editors who provide around-the-clock support and SEO guidance according to information available online. It collaborates with over 500,000 media outlets and influencers globally according to its official website. PR Newswire also offers services such as AI-enhanced content tools and social sharing features as outlined by the company.
Looking ahead, Inhibrx stated it will continue advancing its clinical pipeline while monitoring regulatory developments that could impact future approvals.
